Parte, Capitolo, Paragrafo

 1 I, 1,1(5)   |             Transplantation of Organs and Tissues Between Species.
 2 I, 1,1(7)   |             Transplantation of Organs and Tissues Between Species.
 3 I, 1,1(9)   |             Transplantation of Organs and Tissues Between Species.
 4 I, 2,2(16)  |             et al., Removal of baboon and human antiporcine IgG and
 5 I, 2,2(16)  |             and human antiporcine IgG and IgM natural antibodies by
 6 I, 2,2(16)  | immunoadsorption: Results of in vitro and in vivo studies, Transplantation
 7 I, 2,2(16)  |               Effects of cyclosporine and antibody adsorption on pig
 8 I, 2,2(17)  |               in experimental animals and man, Ann N Y Acad Sci 1966,
 9 I, 2,2(17)  |            Koren E., et al., In vitro and in vivo investigation of
10 I, 2,2(17)  |         anticomplement agents FUT-175 and K76COOH, in the prevention
11 I, 2,2(20)  |        reduces human antibody binding and complement-mediated cytolysis,
12 I, 2,2(21)  |               et al., Pathogenesis of and potential therapies for
13 I, 2,2(22)  |              23; Platt J.L., Lin S.S. and McGregor C.G.A., Acute vascular
14 I, 2,2(24)  |         Xenotransplantation: problems and prospects, Annu.Rev.Med.
15 I, 2,2(27)  |     xenotransplantation: inflammation and apoptosis, Nat. Med 1997.
16 I, 2,3(28)  |               et al., Pathogenesis of and potential therapies for
17 I, 2,3(31)  |              of anti-donor antibodies and complement that precipitate
18 I, 2,3(32)  |        Preformed cytotoxic antibodies and ABO-incompatible grafts,
19 I, 2,3(34)  |             Transplantation of Organs and Tissues Between Species.
20 I, 2,4(41)  |              endogenous retroviruses, and the evolution of retroelements,
21 I, 2,4(41)  |              M. Coffin, S. H. Hughes, and H. E. Varmus eds) Cold Spring
22 I, 3,6(47)  |                immunological barriers and strategies to overcome them,
23 I, 3,6(48)  |   extracorporeal liver support system and clinical results, Ann. NY
24 I, 3,6(49)  |       international society for heart and lung transplantation. The
25 I, 3,6(49)  |         status of xenotransplantation and its potential role in the
26 I, 3,6(49)  |        treatment of end-stage cardiac and pulmonary disease. J. Heart
27 II, 2,12(65)| Xenotransplantation: Science, Ethics, and Public Policy, Washington:
28 II, 2,12(65)|               The Xenotransplantation and Xenozoonose Debate, Journal
29 II, 2,12(65)|              Journal of Law, Medicine and Ethics, 1999, 27: 137-152;
30 II, 2,12(65)|          Healt & Human Services, Food and Drug Administration, Center
31 II, 2,12(65)|              for Biologics Evaluation and Research, Source animal,
32 II, 2,12(65)|         animal, product, preclinical, and clinical issues concerning
33 II, 2,14(69)| animal-to-human transplants, Dialysis and Transplantation, 1995, p.
34 II, 2,16(71)|             persons, informed consent and the assessment of infectious
35 II, 2,17(72)|           Xenotransplantation: ethics and economics, Food Drug Law
36 II, 2,17(72)|         ethical, sociologic, economic and legal aspects of xenotransplantation,
37 II, 2,18(74)|         Intellectual Property: Theory and Practice, Kluwer Law International,
38 II, 3,21(75)|               US Department of Health and Human Services Committee
39 II, 3,21(75)|         Interim Regulatory Authority, and the Italian Xenotransplantation
40 II, 3,21(75)|             National Ethics Committee and applications for clinical
41 II, 3,21(75)|           Security of Health Products and of the Ministry of Health.